BioChem Troxatyl
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NDA filing for DNA polymerase inhibitor troxacitabine planned for the end of 2001 for treatment of blastic phase chronic myelogenous leukemia. The leukemia therapy will be marketed by Shire after the planned merger of BioChem and Shir